On August 4, 2022 AnHeart Therapeutics reported it will host an investigator meeting in addition to a e-poster presentation at the World Conference on Lung Cancer (WCLC) in Vienna, Austria at 11:00 am ET on Sunday, Aug. 7, 2022 (Press release, AnHeart Therapeutics, AUG 4, 2022, View Source [SID1234617605]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ignatius Ou, M.D., Ph.D., Professor of Medical Oncology, University of California Irvine School of Medicine, along with members of AnHeart’s clinical development team and study investigators, will discuss the most recent clinical data of taletrectinib and the current status of the TRUST-II clinical trial for its ROS-1 inhibitor taletrectinib in ROS1-positive non-small cell lung cancer (NSCLC).
Taletrectinib received FDA granted Breakthrough Therapy Designation (BTD) for the treatment of adult patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who are ROS1 tyrosine kinase inhibitor (TKI) treatment naïve or previously treated with crizotinib.
Details of the e-poster presentation at WCLC 2022:
Abstract Title: TRUST-II: A Global Phase II Study for Taletrectinib in ROS1-fusion Positive Lung Cancer and Other Solid Tumors
Session: EP08.02 – Metastatic Non-small Cell Lung Cancer – Molecular Targeted Treatments
Final Program #: EP08.02-118
Author: Misako Nagasaka, M.D. Ph.D., University of California Irvine, School of Medicine
E-posters will be displayed on both days of the conference from August 7-8, 2022, 09:45 – 18:00. For more information, visit: View Source
The e-poster, as with other selected presentations regarding developments in AnHeart’s business given by management at certain investor and medical conferences, can be found on the company’s website, www.anhearttherapeutics.com, under Publications.